Print

Alzheimer's Drug from Pfizer Inc. (PFE), Johnson & Johnson (JNJ) May Prove Safer  
7/20/2011 7:38:36 AM

Experimental Alzheimer's drug bapineuzumab, from Pfizer (PFE.N) and Johnson & Johnson (JNJ.N), may be safer than originally thought, according to two studies by U.S. researchers released on Wednesday. They said that a brain swelling condition called vasogenic edema, which caused a lot of worry over the drug's safety early on, may decrease over time. "It looks like we can treat people for a number of years safely," Dr. Steven Salloway of Butler Hospital and Brown University in Providence, Rhode Island, told the Alzheimer's Association International Conference in Paris.